Introduction: We investigated factors affecting Virological failure (VF) on first line Antiretroviral Therapy (ART) and evaluated a pragmatic
Introduction
Antiretroviral therapy (ART) has changed the natural history of HIV infection [1] . By the end of 2015 about 36.7 million individuals were living with HIV globally and 25.8 million of these were living in subSaharan Africa (SSA) [2, 3] . By June 2016, ART coverage had increased to 46% globally and 54% in SSA [2] . Uganda's HIV prevalence by 2014 was estimated at 7.4% and out of the estimated 1.5 million people living with HIV-AIDS (PLWHA)by the end of 2014, 0.75 million people were on ART and about 10% of these had HIV viral load of above 1000 copies/ml [4] . ART initiation reduces HIV replication in peripheral blood [5] [6] [7] [8] suppresses plasma HIV viral loads (VL) to unquantifiable levels within 4-6 months [9, 10] , reduces morbidity and mortality, with resultant improvement in survival [1, 5] . If adequate viral suppression is not achieved, therapy is considered to be failing and may require switching to a second line ART regimen [11, 12] Many other factors are independently associated with failure to achieve optimal HIV viral suppression [19] . Knowledge of such predictors will enable clinicians forecast ART outcomes and design interventions to prevent virological failure and meet the UNAIDS 90-90-90 treatment targets. Diagnosis of virological failure based on a single plasma VL measurement of > 1000 copies/ml or two successive VL measurements above 400 copies/ml, at any time after 6 months on ART, (conventional VF), has led to unnecessary switching from first to second line ART regimen which is costly and almost currently the last available treatment option in most SSA countries [22] . If patients with detectable VL after 6 months on ART receive further intensified ART adherence counselling and continue on first-line ART for another 6 months, only those whose VL remains >1000 copies/ml (true or pragmatic virological failure) are then switched to second-line ART. Until HIV drug resistance testing is widely available in public HIV care settings, identifying patients with true or pragmatic virological failure provides a more reliable criterion for switching patients failing on first line ART to second line ART.
Studies in developed countries have evaluated switch strategies as a basis of enhancing cost savings in an era of global economic recession [23] . In this study, we assessed factors affecting virological failure using both the conventional and pragmatic definitions and justified the use of pragmatically defined virological failure while switching patients to second line ART. The study findings add to the body of knowledge on ART switching practices in resource limited settings and enhances prediction of virological failure risk so as to improve ART treatment outcomes. (Roche, Roche molecular systems, NJ, USA) assay was used (lower detection limit of 400 copies per ml).
Methods

Data management and statistical analysis
Software and participant follow up: Data was managed using an Ms Access database and was analysed in Stata version 13.0.
Participants' characteristics at ART initiation between January 2004
and March 2011 were summarised by cross tabulation. The study had outcomes based on 2 virological failure definitions (conventional and pragmatic) at different time points. A participant's follow-up started at ART initiation and ended at the earliest time of diagnosis of virological failure, death, loss to follow up, or date last seen (whichever was first). Loss to follow up was defined as being late for 3 months or more after the next scheduled quarterly visit and still known to be alive. Participants were censored at the end of the study.
Ethics and consent: this study was approved by the Science and
Ethics Committee of the Uganda Virus Research Institute and the Uganda National Council for Science and Technology. Participants gave signed or thumb-printed written informed consent to participate in the study and confidentiality procedures were adhered to throughout the study Outcome: The main outcome was virological failure. Conventional virological failure was defined as a single VL of > 1000 copies/ml or two successive VL > 400 copies/ml taken 6 months apart from a participant on ART for 6 months or more. Participants with conventional virological failure received intensified adherence counselling and continued on first line ART for 6 more months after which those with persistent VL > 1000 copies/ml were regarded to be true or Pragmatic failures and all were switched to second line ART regimen.
Exposures:
The main exposure was ART adherence which was measured monthly at each ART refill visit using both self-report and pill count. Participants reported the number of days they missed taking their doses over the previous four days and since the last ART refill visit. Adherence was categorised as: good (> 95%) if no doses were skipped over the last 4 days or since the last refill visit and poor (<95%) if any doses were missed over the same period.
ART adherence data for each participant over the entire follow up period or up to the visit of virological failure was collapsed to create an overall adherence summary measure. The proportion of visits with good adherence was presented for each participant as categorical for crude analysis. In addition, the continuous variable (proportion of visits with good adherence) was rescaled so that 1 unit represented a 10% decrease in the proportion of visits with good adherence (e.g. from 100% to 90%) and this was used in the regression model. Secondary exposures included characteristics measured at ART initiation including gender, age, marital status, number of partners, occupation, alcohol consumption, CD4 counts, HIV viral loads, weight and body mass index (BMI).
Conceptual framework: Our analysis was based on a conceptual framework which assumed; ART adherence was independently 
Effect of adherence on conventional virological failure:
Overall, 84 (26.6%) participants developed conventional virological failure, a rate of 8.6 per 100 pyar. There were no significant differences in failure rates by gender, age and alcohol consumption.
The median proportion of visits on which good adherence was reported was 97.0% (IQR (92-100). Conventional failure rates were significantly higher among participants who reported adherence less than 90% compared with participants who reported good adherence of above 95% of the visits (crude HR 1.38 for linear association with 10% drop in the proportion of visits with good adherence, 95% CI 1.23-1.55, P<0.001) ( Table 2 ).
Effect of adherence on pragmatic virological failure:
After the intensified ART adherence counselling, 28 (33.3%) of the 84 participants with conventional failure still had persistent VL > 1000 copies/ml, a pragmatic failure rate of 2.7 per 100 pyar. The pragmatic failure rate decreased significantly with increasing age (P = 0.04), but increased with decrease in proportion of visits on which good adherence was reported (P < 0.001) ( Table 3 ). The unadjusted linear hazard ratio indicated that pragmatic failure rate increased by 45.0% for every 10% decrease in the proportion of visits on which good adherence was reported (HR 1.45, 95%CI
1.26-1.71; P < 0.001). After adjusting for age, gender, alcohol consumption, baseline CD4 counts and baseline VL, the adjusted linear hazard ratio for the failure rate per 10% decrease in the proportion of visits on which good adherence was reported increased to 2.12 (95%CI 1.61-2.79, P < 0.001).
Independent predictors of conventional virological failure:
After adjusting for age and gender, the only independent predictors of conventional virological failure were adherence and alcohol consumption. For each drop of 10% in the proportion of visits at which a participant achieved good adherence, the rate of failure increased by 83% (aHR 1.83, 95%CI 1.50-2.23, P < 0.001).
Participants who consumed alcohol had 71% higher rate of conventional virological failure than those who reported not consuming alcohol (aHR 1.71, 95%CI 1.05-2.79, P = 0.03) ( Table   4 ).
Independent predictors of pragmatic failure among individuals with conventional failure:
We adjusted for apriori confounders; age, gender and alcohol consumption to determine predictors of pragmatic virological failure among participants with conventional virological failure. There was an 88% reduction in the odds of pragmatic failure from age group < 30 years to age group 30-39 years (adjusted odds ratio (aOR) 0.12, 95% CI 0.03-0.57, P = 0.01) and an 86% reduction in the odds of pragmatic failure from age group <30 years to age group 40 years and above (aOR = 0.14, 95%CI (0.03-0.71) P = 0.02). There was borderline evidence of a threefold increase in the odds of pragmatic failure among participants who reported consuming alcohol compared to those who reported not consuming alcohol (aOR = 3.14, 95% CI 0.95-10.34), P = 0.06). However, adherence was not significantly associated with pragmatic failure among participants with conventional failure (P = 0.44) ( Table 5 ).
Discussion
In Death, migration and missed appointments were well recorded and loss to follow up was low at 3.2%, which minimised the likelihood of selection bias. The few participants with missing baseline data were comparable to those without missing data. Regular viral loads measurement reduced the likelihood of misclassification of outcome.
Participants were recruited from a general population based cohort minimising selection bias and enhancing generalizability of findings.
The study had a robust data collection mechanism, with trained staff and laboratory equipment were subjected to regular external validity checks and quality assurance to minimise errors in the measurement of viral load and CD4 count.
Limitations: Our estimates were subjected to random error by having few participants aged below 30 years and above 50 years.
This undermined exploration of the age effect like to find the actual age below or above which failure is more or less likely. 
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